rosuvastatin + placebo
Phase 1Completed 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Atherosclerosis
Conditions
Atherosclerosis, Inflammatory Activity in Carotid Arteries
Trial Timeline
Dec 1, 2007 โ Jun 1, 2009
NCT ID
NCT00689416About rosuvastatin + placebo
rosuvastatin + placebo is a phase 1 stage product being developed by AstraZeneca for Atherosclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00689416. Target conditions include Atherosclerosis, Inflammatory Activity in Carotid Arteries.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02546323 | Phase 3 | Completed |
| NCT00929734 | Phase 2 | Completed |
| NCT00951132 | Phase 2 | Withdrawn |
| NCT00990028 | Phase 1/2 | Completed |
| NCT00783042 | Phase 1 | Completed |
| NCT00673582 | Approved | Terminated |
| NCT00689416 | Phase 1 | Completed |
| NCT00329758 | Phase 2 | Completed |
| NCT00355615 | Phase 3 | Completed |
| NCT00658463 | Approved | Completed |
| NCT00800800 | Phase 3 | Completed |
Competing Products
20 competing products in Atherosclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Orforglipron + Placebo | Eli Lilly | Phase 3 | 77 |
| Olmesartan medoxomil + Placebo | Daiichi Sankyo | Phase 3 | 77 |
| Pactimibe sulfate | Daiichi Sankyo | Phase 2/3 | 65 |
| Pactimibe | Daiichi Sankyo | Phase 2 | 52 |
| Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin | Daiichi Sankyo | Phase 3 | 77 |
| Micronized 17B-estradiol | Johnson & Johnson | Phase 2/3 | 65 |
| Rosuvastatin + placebo + aspirin + placebo | AstraZeneca | Approved | 85 |
| Rosuvastatin + Placebo | AstraZeneca | Approved | 85 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 1 | 33 |
| Rosuvastatin + Atorvastatin | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin (5mg๏ผ10mg๏ผ20mg) + Rosuvastatin 5mg | AstraZeneca | Approved | 85 |
| Vorapaxar + Placebo | Merck | Phase 3 | 77 |
| Vorapaxar + Placebo + Aspirin + Clopidogrel | Merck | Phase 2 | 52 |
| Niacin/simvastatin compared to simvastatin alone at 2 doses | Merck | Approved | 85 |
| lovastatin | Merck | Phase 2/3 | 65 |
| Ezetimibe + Placebo | Merck | Approved | 85 |
| Vorapaxar + Placebo | Merck | Phase 3 | 77 |
| Niaspan | Merck | Pre-clinical | 23 |
| MK0633 | Merck | Phase 2 | 52 |